Partners

We’re seeking partnerships with anyone interested in improving outcomes for children and young people with cancer.

This includes research institutions, universities, specialist hospitals, research funders, biopharmaceutical companies, contract research organisations, charities, impact investors, philanthropists, foundations, family offices, regulatory experts, economists, think tanks and more.

C-Further is a brand owned by Cancer Research UK, created to unite diverse organisations to partner with C-Further under a common shared mission and identity. Cancer Research UK is a company limited by guarantee and a registered charity.

Our initial investment will allow us to take several projects on in the initial 5-year term. However, we want to build this into a sustainable initiative which enables the development of childhood cancer therapeutics in the long term. We intend to proactively manage and refresh our portfolio by sourcing and launching new projects as existing projects naturally come to an end.

C-Further is operating at an international level and seeks to work with all organisations that can make a meaningful contribution towards realising our mission sooner. Our membership model seeks to accommodate the needs of diverse organisations regardless of their size, location or mandate, enabling partnerships that are meaningful and mutually beneficial.

C-Further’s founders have considerable expertise in drug discovery and have brought multiple new drugs to market in a variety of diseases including adult cancers over the last 20 years, working with a wide variety of partners globally to achieve this. We are committed to translating research into meaningful therapies focused on cancers affecting children and young people, as outlined in Cancer Research UK’s Research Strategy and LifeArc’s Childhood Cancer Translational Challenge.

Cancer Research UK's Research Strategy

LifeArc’s Childhood Cancer Translational Challenge

We are keen to partner with like-minded organisations to continually grow the consortium’s potential and achieve the maximum impact possible for children and young people affected by cancer.

We acknowledge the scale of the challenge of discovering, developing and commercialising new bespoke treatments for children and young people with cancer, and that drug discovery is only the first step on that journey. Ultimately, we seek to develop a pipeline of pre-clinical therapeutics across diverse indications and utilising varied modalities. We are actively engaged with key thought leaders about how to solve the downstream challenges of funding clinical development and future commercialisation of new therapies. By partnering with us you increase the chance that more effective treatments with fewer side effects reach children and young people with cancer sooner.

Whether you are a research institute, charity, foundation, philanthropist, or company, C-Further has established a partnerships team to efficiently answer your questions and drive forward partnering discussions with you. If you are interested in learning more, please contact us at info@c-further.org.